System Guide
Back to Search Results

Search Results

Display Options
Display Options
Select Fields
Export Results to CSV Create Report 0
+ Add all results to report

Report Produced: 12/23/2025 00:21 AM

Report Question ID Question
20031200 Reportability/Terminology, NOS--Hematopoietic, NOS: Is "smoldering" multiple myeloma reportable to SEER?
20031199 CS Extension/Polyp--Colon: How is CS extension coded for tumor invasion described as "Haggitt level 4"? See Description.
20031198 Surgery of Primary Site/Date Therapy Initiated--Head & Neck: Would a biopsy, NOS, that removed the majority of the tumor be used to code these fields? See Description.
20031196 EOD-Pathological Extension--Prostate: How is this field coded when biopsy findings differ from prostatectomy findings? See Description.
20031195 EOD-Clinical Extension--Prostate: Is this field coded to 15 [Tumor identified by needle biopsy for elevated PSA] when it is unknown whether or not a TRUS was done? See Description.
20031194

Terms of involvement--Lung: Is "intense uptake" described on a PET scan an indication of involvement? See Description.

20031193 Surgery of Primary Site--Lung: Is a core-out of the main bronchus coded in this field? See Description.
20031192 EOD-Extension--Breast: How is this field coded when the diagnosis includes both invasive and in situ disease, and the pathology report stated the tumor size may or may not include the size of the in situ portion of the tumor? See Description.
20031191 EOD-Clinical Extension--Prostate: How is this field coded when biopsies of the prostatic apex are positive and the physician clinically stages the case as T1c?
20031189 Multiple Primaries (Pre-2007)--Thyroid: Would a papillary carcinoma of the right lobe of the thyroid diagnosed approximately 2 1/2 years after a papillary carcinoma of the left lobe be coded as a second primary? See Description.